WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search

QL ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
QL01 ANTINEOPLASTIC AGENTS
QL01X OTHER ANTINEOPLASTIC AGENTS
QL01XE Protein kinase inhibitors
QL01XE01 imatinib
QL01XE02 gefitinib
QL01XE03 erlotinib
QL01XE04 sunitinib
QL01XE05 sorafenib
QL01XE06 dasatinib
QL01XE07 lapatinib
QL01XE08 nilotinib
QL01XE09 temsirolimus
QL01XE10 everolimus
QL01XE11 pazopanib
QL01XE12 vandetanib
QL01XE13 afatinib
QL01XE14 bosutinib
QL01XE15 vemurafenib
QL01XE16 crizotinib
QL01XE17 axitinib
QL01XE18 ruxolitinib
QL01XE19 ridaforolimus
QL01XE21 regorafenib
QL01XE22 masitinib
QL01XE23 dabrafenib
QL01XE24 ponatinib
QL01XE25 trametinib
QL01XE26 cabozantinib
QL01XE27 ibrutinib
QL01XE28 ceritinib
QL01XE29 lenvatinib
QL01XE31 nintedanib
QL01XE32 cediranib
QL01XE33 palbociclib
QL01XE34 tivozanib
QL01XE35 osimertinib
QL01XE36 alectinib
QL01XE37 rociletinib
QL01XE38 cobimetinib
QL01XE39 midostaurin
QL01XE40 olmutinib
QL01XE41 binimetinib
QL01XE42 ribociclib
QL01XE43 brigatinib
QL01XE44 lorlatinib
QL01XE45 neratinib
QL01XE46 encorafenib
QL01XE47 dacomitinib
QL01XE48 icotinib
QL01XE50 abemaciclib
QL01XE91 toceranib

Last updated: 2019-01-21